Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Effectiveness of 23-valent pneumococcal polysaccharide vaccine on diabetic elderly.

Kuo CS, Lu CW, Chang YK, Yang KC, Hung SH, Yang MC, Chang HH, Huang CT, Hsu CC, Huang KC.

Medicine (Baltimore). 2016 Jun;95(26):e4064. doi: 10.1097/MD.0000000000004064.

2.

Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects.

Ciprero K, Zykov KA, Briko NI, Shekar T, Sterling TM, Bitieva E, Stek JE, Musey L.

Hum Vaccin Immunother. 2016 May 5:1-6. [Epub ahead of print]

PMID:
27149114
3.

Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid).

Esposito S, Bonanni P, Maggi S, Tan L, Ansaldi F, Lopalco PL, Dagan R, Michel JP, van Damme P, Gaillat J, Prymula R, Vesikari T, Mussini C, Frank U, Osterhaus A, Celentano LP, Rossi M, Guercio V, Gavazzi G.

Hum Vaccin Immunother. 2016 Jul 2;12(7):1777-94. doi: 10.1080/21645515.2016.1150396. Epub 2016 May 2.

PMID:
27135390
4.

Pneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right?

Papadatou I, Spoulou V.

Clin Vaccine Immunol. 2016 May 6;23(5):388-95. doi: 10.1128/CVI.00721-15. Print 2016 May. Review.

PMID:
27009210
5.

Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes.

Ciprero KL, Marchese RD, Richard P, Baudin M, Sterling TM, Manoff SB, Radley D, Stek JE, Soubeyrand B, Grabenstein JD, Samson SI, Musey LK.

Hum Vaccin Immunother. 2016 Mar 22:1-7. [Epub ahead of print]

PMID:
27002793
6.

Advances in the prevention, management, and treatment of community-acquired pneumonia.

Pletz MW, Rohde GG, Welte T, Kolditz M, Ott S.

F1000Res. 2016 Mar 8;5. pii: F1000 Faculty Rev-300. doi: 10.12688/f1000research.7657.1. eCollection 2016. Review.

7.

Efficacy of PPV23 in Preventing Pneumococcal Pneumonia in Adults at Increased Risk--A Systematic Review and Meta-Analysis.

Schiffner-Rohe J, Witt A, Hemmerling J, von Eiff C, Leverkus FW.

PLoS One. 2016 Jan 13;11(1):e0146338. doi: 10.1371/journal.pone.0146338. eCollection 2016. Review.

8.

A comparative public health and budget impact analysis of pneumococcal vaccines: The French case.

Jiang Y, Gervais F, Gauthier A, Baptiste C, Martinon P, Bresse X.

Hum Vaccin Immunother. 2015;11(9):2188-97. doi: 10.1080/21645515.2015.1011957. Epub 2015 Aug 12.

9.

Effect of the adult pneumococcal polysaccharide vaccine on cardiovascular disease: a systematic review and meta-analysis.

Ren S, Newby D, Li SC, Walkom E, Miller P, Hure A, Attia J.

Open Heart. 2015 Jun 26;2(1):e000247. doi: 10.1136/openhrt-2015-000247. eCollection 2015. Review.

10.

The ABC of pneumococcal infections and vaccination in patients with chronic kidney disease.

Vandecasteele SJ, Ombelet S, Blumental S, Peetermans WE.

Clin Kidney J. 2015 Jun;8(3):318-24. doi: 10.1093/ckj/sfv030. Epub 2015 May 7.

11.

Association between monovalent influenza A (H1N1) pdm09 vaccine and pneumonia among the elderly in the 2009-2010 season in Japan: A case-control study.

Kondo K, Suzuki K, Washio M, Ohfuji S, Fukushima W, Maeda A, Hirota Y; Pneumonia in Elderly People Study Group.

Hum Vaccin Immunother. 2015;11(5):1088-93. doi: 10.1080/21645515.2015.1016668. Erratum in: Hum Vaccin Immunother. 2015;11(10):2510.

12.

A cluster-randomized controlled trial of a multicomponent intervention protocol for pneumonia prevention among nursing home elders.

Juthani-Mehta M, Van Ness PH, McGloin J, Argraves S, Chen S, Charpentier P, Miller L, Williams K, Wall D, Baker D, Tinetti M, Peduzzi P, Quagliarello VJ.

Clin Infect Dis. 2015 Mar 15;60(6):849-57. doi: 10.1093/cid/ciu935. Epub 2014 Dec 16.

13.

Recommendations for pneumococcal immunization outside routine childhood immunization programs in Western Europe.

Castiglia P.

Adv Ther. 2014 Oct;31(10):1011-44. doi: 10.1007/s12325-014-0157-1. Epub 2014 Oct 10. Review.

14.

Management of community-acquired pneumonia in older adults.

Simonetti AF, Viasus D, Garcia-Vidal C, CarratalĂ  J.

Ther Adv Infect Dis. 2014 Feb;2(1):3-16. doi: 10.1177/2049936113518041. Review.

15.

Microbial aetiology, outcomes, and costs of hospitalisation for community-acquired pneumonia; an observational analysis.

Spoorenberg SM, Bos WJ, Heijligenberg R, Voorn PG, Grutters JC, Rijkers GT, van de Garde EM.

BMC Infect Dis. 2014 Jun 17;14:335. doi: 10.1186/1471-2334-14-335.

16.

Community-acquired pneumonia caused by carbapenem-resistant Streptococcus pneumoniae: re-examining its prevention and treatment.

Doi A, Iwata K, Takegawa H, Miki K, Sono Y, Nishioka H, Takeshita J, Tomii K, Haruta T.

Int J Gen Med. 2014 May 21;7:253-7. doi: 10.2147/IJGM.S63744. eCollection 2014.

17.

Persistence and complex evolution of fluoroquinolone-resistant Streptococcus pneumoniae clone.

Ben-David D, Schwaber MJ, Adler A, Masarwa S, Edgar R, Navon-Venezia S, Schwartz D, Porat N, Kotlovsky T, Polivkin N, Weinberg I, Lazary A, Ohana N, Dagan R.

Emerg Infect Dis. 2014 May;20(5):799-805. doi: 10.3201/eid2005.130142.

18.

Cost-effectiveness of pneumococcal vaccines for adults in the United States.

Chen J, O'Brien MA, Yang HK, Grabenstein JD, Dasbach EJ.

Adv Ther. 2014 Apr;31(4):392-409. doi: 10.1007/s12325-014-0115-y. Epub 2014 Apr 10.

19.

Pneumococcal vaccination rates in adults in Germany: an analysis of statutory health insurance data on more than 850,000 individuals.

Theidel U, Kuhlmann A, Braem A.

Dtsch Arztebl Int. 2013 Nov 1;110(44):743-50. doi: 10.3238/arztebl.2013.0743.

20.

Infection prevention in long-term care: a systematic review of randomized and nonrandomized trials.

Uchida M, Pogorzelska-Maziarz M, Smith PW, Larson E.

J Am Geriatr Soc. 2013 Apr;61(4):602-14. doi: 10.1111/jgs.12175. Epub 2013 Mar 21. Review.

Items per page

Supplemental Content

Write to the Help Desk